Clinical Trial Update: An Expanded Safety Study of Dapivirine Gel 4759 in Africa [Phase 1, Phase 2]

View source ↗

Summary

An expanded safety study of Dapivirine Gel 4759 for HIV prevention completed across Phase 1 and Phase 2 in Africa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immune Deficiency Syndrome
• HIV Infection

Drugs mentioned

• Dapivirine Gel 4759 (dapivirine)

Snippet

Sponsor: International Partnership for Microbicides, Inc. | Conditions: HIV Infections, Acquired Immunodeficiency Syndrome | Phase 1, Phase 2 | Status: COMPLETED